Replacement therapy in inherited factor VII deficiency: Occurrence of adverse events and relation with surgery by Napolitano, M. et al.
LETTER TO THE EDITOR
Replacement therapy in inherited factor VII deficiency:
occurrence of adverse events and relation with surgery
M. NAPOLITANO,* A. DOLCE,† A. BATOROVA,‡ M. GIANSILY-BLAIZOT,§ J . INGERSLEV,¶
N. MIRBEHBAHANI,** M. N. D. DI MINNO,†† M. F. LOPEZ FERNANDEZ,‡‡ M. KARIMI,§§
P. CHAROENKWAN,¶¶ K. KAVAKLI*** and G. MARIANI†††
*Haematology Unit, Thrombosis and Hemostasis Reference Regional Center, Universita di Palermo; †National Institute of
Statistics, Palermo, Italy; ‡The National Haemophilia Centre, Institute of Haematology and Blood Transfusion, University
Hospital, Bratislava, Slovakia; §Laboratory of Haematology, University Hospital, Montpellier, France; ¶Centre for
Haemophilia & Thrombosis, University Hospital Skejby, Aarhus, Denmark; **Hematology and Oncology Research Center,
Golestan University of Medical Sciences, Gorgan, Iran; ††Department of Clinical Medicine and Surgery, Federico II
University, Naples, Italy; ‡‡Complejo Hospitalario Universitario A Coru~na, A Coru~na, Spain; §§Haematology Research
Center, Shiraz University of Medical Sciences, Shiraz, Iran; ¶¶Division of Hematology, Chiang Mai University, Chiang Mai,
Thailand; ***Children’s Hospital, Ege University Faculty of Medicine, Izmir, Turkey; and †††Universita di Ferrara Medical
School, Ferrara, Italy
The treatment paradigm for bleeding management in
patients with congenital bleeding disorders is Replace-
ment Therapy (RT), based on the substitution of the
missing coagulation factor, with the aim of correcting
the clotting defect. For the management of patients
with factor VII (FVII) deficiency, a rare bleeding disor-
der, a number of therapies are available, including
plasma or plasma-derived products as well as recom-
binant products [1,2]. However, information regard-
ing optimal treatment schedules, treatment limitations
and Adverse Events (AEs) is currently limited to anec-
dotal reports [3–8]. As a consequence, RT administra-
tion is influenced by factors such as the rarity of the
disorder, the type, availability and supply of products,
as well as economic and geographical factors.
It is taken for granted that all RT types and sched-
ules are associated with potential side-effects, and
there is no doubt that the management of patients
with bleeding disorders can be improved by reducing
the occurrence of AEs and their severity. Awareness of
AEs is indeed a relevant issue in the management of
rare bleeding disorders, where data collection, espe-
cially in a prospective fashion, is very difficult.
The Seven Treatment Evaluation Registry (STER)
has prospectively collected a large amount of informa-
tion on the management of patients with congenital
FVII deficiency [9–13]. The aim of this study was the
systematic analysis of AEs related to treatments, for
prophylaxis [9], surgical interventions [10,12] and
spontaneous or traumatic bleeding episodes [11].
Patients with congenital FVII deficiency managed
for a large array of clinical indications were investi-
gated for RT-related AEs during the 8-year duration
of the STER (deadlock date: February 28th, 2012).
STER was a prospective, observational, multicentre,
web-based registry created to collect and describe data
on treatment modalities and outcomes in patients with
this rare bleeding disorder. All treatment procedures
were in accordance with the ethical standards and
approved by the Ethics Committee of L’Aquila
University Hospital (coordinator’s institution) and the
committees of all the other enrolling centres. Decisions
on type of RT and schedules were autonomously
taken by enrolling physicians.
Because of different viral ecologies, treatment atti-
tudes and laboratory issues, pharmacovigilance was
limited to non-blood-borne virus-related AEs; deci-
sions on RT type and schedules were taken autono-
mously by the enrolling physicians. The STER study
protocol was designed to capture the following ele-
ments related to AEs: clinical description, evaluation
of severity (serious or non-serious), potential associa-
tion with type of treatment (likely or unlikely) and
outcome (including mortality for any reason). Throm-
bosis diagnosis (venous or arterial) was based on clini-
cal suspicion and confirmed by imaging. FVII: c was
determined at baseline and 15 min after the first RT
administration for the treatment reported. STER pro-
tocol was designed to centrally determine inhibitors at
the following time points: first enrolment (before RT
administration), 30 days follow-up after the reported
RT and when needed for clinical suspicion. Screening
for inhibitory antibodies to FVII was conducted in a
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centralized fashion [4,13]; only baseline samples with
FVII:c <4% were considered for inhibitor assay.
Enrolling physicians were asked to carefully describe
the type of AE, timing of occurrence after RT, clinical
management and outcome. AEs were evaluated at the
time of treatment and at the 30-day follow-up visit
(or later if needed). Data were obtained from the
STER database and analysed following a data quality
and consistency check according to the STER data-
management plan. We calculated the cumulative inci-
dence rate of AEs in our cohort as the number of new
cases per population at risk in a 8 years observational
period and the incidence density rate (or person-time
incidence rate) as number of new cases per population
at risk in a given time period when the denominator is
the sum of the person-time of the at risk population.
With regard to every type of AE, we also calculated
the prevalence in our cohort for specific adverse events
as the proportion of cases in the population at the end
of the study. Analyses were performed using the MEDI-
CAL
 software version 7.4.1.2 (http: www.med-
calc.org). We here focus on inhibitor development and
thrombosis, being these considered the most relevant
AEs related to RT. Other side-effects reported after
RT (n = 11) consisted mainly in re-bleeding (n = 4)
and aspecific symptoms like headache, virosis and
fever, judged as unlikely related to RT (n = 7). STER
overall enrolled 225 patients with congenital FVII
deficiency and a total of 312 treatments were adminis-
tered: recombinant activated FVII (rFVIIa, Novo
Seven, Novo Nordisk A/S, Denmark, n = 245
[78.5% of all replacement therapies]); plasma-derived
FVII concentrates (pd-FVII, Facteur VIITM LFB, Cour-
taboef, France or Provertin-UM TIM3TM, Baxter,
Vienna, Austria; FVII NF, Baxter, n = 31, 9.9%);
Fresh Frozen Plasma (FFP), n = 30, 9.6%); Prothrom-
bin Complex Concentrate (PCC, Prothromplex TIM
3, Baxter; Prothromplex Total TIM 4, Baxter, n = 5,
1.6%), and in one case FEIBA (Baxter). The AE’s
cumulative incidence was (2.2%, CI 0.6–3.9%) and
the incidence density rate was 1.6% (CI 0.0–2.5%)
per year. As for FVII inhibitors, 115 patients were
centrally tested using a standardized modification in
the Bethesda assay. Inhibitors occurred in two of those
patients in whom a centralized screening could be
done (n = 125); two other inhibitor patients were
enrolled in the STER but inhibitor could not be cen-
trally confirmed for logistical reasons. Three of the
four reported inhibitors were detected during prophy-
laxis with rFVIIa, in two young boys at the age of
5 years and 1 year, respectively, and in one infant (a
5 months old male).
All cases had a very severe bleeding phenotype
(epistaxis, easy bruising, gastrointestinal bleeding,
CNS bleeding, subcutaneous and muscle haematoma).
Baseline FVII:c levels were 2, 1.3 and <1% respec-
tively. All the three patients were previously exposed
to multiple FFP infusions and prophylaxis with
rFVIIa was instituted to prevent CNS (in two cases)
and GI (in one case) bleedings. The immune response
in FVII deficiency was not complicated by anaphylac-
tic reactions. Prophylaxis was continued in all three
patients without any safety problem or reported dose-
adjustment. All the patients were high responders
with peak titres of between 34 and 68.3 BU mL1
(Table 1) at the last available follow-up (1 month
after detection).
One case of inhibitor was detected in adulthood, in
a 53 year-old woman previously treated with FFP, pd-
FVII and PCC for recurrent bleeding episodes (mainly
gynaecological). Inhibitor was discovered when the
patient underwent multiple dental extractions, the
patient was treated with rFVIIa given at an initial
dose of 30 lg kg1 followed by eight consecutive
boluses of 10 lg Kg1. Patients were not reported to
undergo any specific treatment for inhibitor eradica-
tion (Table 1).
Thrombosis occurred in three patients: two cerebral
infarctions and one superficial vein thrombosis (1% of
treatments). Dosing and treatment schedules are
shown in the Table 1.
In the first case (M/8), treated for the evacuation of
left cerebellar haematoma, RT with rFVIIa lasted
8 days; rFVIIa was administered immediately before
the procedure and for the following 7 days at a dose
of 18 lg Kg1 every 6 h. FFP was than administered
up to 16 days post procedure at a dose of 10 U Kg1,
every 6 h.
In the second case (M/23), treated for knee replace-
ment, RT with rFVIIa was given before the procedure
and every 12 h in the following 24 h after orthopaedic
surgery at a dose of 30 lg Kg1. Superficial Vein
Thrombosis (SVT), confirmed with Doppler ultra-
sounds, involved the cephalic vein of the right arm.
In the third case (M/53), treated for kidney trans-
plant, rFVIIa was administered 30 min before the pro-
cedure and 15 min thereafter. After 1 h, the dose of
rFVIIa was empirically lowered to 22.5 lg kg1; after
4 h, rFVIIa was given at 15 lg kg1. The following
RT administrations occurred at 8, 18, 24 and 30 h
after the first one, namely at a doses of 15 lg kg1.
Starting from 36 h, rFVIIa (15 lg kg1) was adminis-
tered every 6 h until 96 h (day 4), when the same
dose was injected twice a day for the following
6 days. The patient was discharged under immunosup-
pressive drugs. At 30 days follow-up visit he presented
with a paralysis of the right leg started 48 h before
admission, a CT scan confirmed the involvement of
the left anterior cerebral artery and the patient was
treated with Low Molecular Weight Heparin
(LMWH) at prophylactic dose for 2 weeks, without
any bleeding complication and a partial relief of paral-
ysis. Further RT was not administered during
LMWH.
Haemophilia (2015), 1--4 © 2015 John Wiley & Sons Ltd
2 LETTER TO THE EDITOR
Inhibitors to FVII were considered the most impor-
tant side-effect associated with RT; we, therefore, per-
formed a screening using a standardized modification
in the Bethesda assay in a centralized fashion [4,6,13].
Of the two inhibitors screened and confirmed by the
Central Laboratory, one had been previously detected;
one was a de novo event. FVII gene mutation is avail-
able only for two patients with inhibitors (one with a
missense mutation plus one codon deletion and
another homozygous for a nonsense mutation).
Inhibitor occurrence in FVII deficiency can be con-
sidered at least as rare as that currently reported in
haemophilia B [6], where a prevalence of 2–3% is
accepted. Comparison to FIX deficiency is the most
reasonable one, due to a high comparability in the
gene and protein structures of FIX and FVII, even
though severe gene defects, such as large deletions,
have not been reported in patients with FVII defi-
ciency [14]. Another substantial difference between
the two bleeding disorders is the occurrence of ana-
phylactic reactions, a severe clinical issue in patients
with haemophilia B, that is absent in patients with
inhibitors to FVII, as confirmed by the fact that pro-
phylaxis in FVII-deficient patients, can be continued
even in the presence of an inhibitor [13]. Two other
cases of inhibitor were reported in the STER but inhi-
bitor detection could not be determined in a central-
ized fashion. Considering the total number of patients
enrolled in the STER (n = 225), the prevalence (1.8%)
appears unchanged.
The prevalence rate of thrombosis in the STER
was 1% (3/312 treatments). This prevalence is the
same as that found in a retrospective study by our
group [5].
Postinfusion FVII coagulant activity levels did not
differ between those patients experiencing AEs and
the other uncomplicated treatments (data not shown),
and no relationship could be established between
thrombosis occurrence and the dose of rFVIIa or
patient’ age. The association between gene mutations
and the risk of thrombosis has been explored [5] but
even if two common mutations (Arg364Gln and
Ala354Val) have been frequently detected in patients
with thrombosis, no specific association has been
found [5]. Thrombophilias, such as FV Leiden, pro-
thrombin gene mutation, antiphospholipid antibodies
syndrome and elevated clotting FVIII levels, were pre-
sent in some cases of FVII deficiency with thrombosis,
but they did not seem to play a relevant role as risk
factors for thrombosis, since thrombophilia markers
appeared to have a similar prevalence in patients with
and without thrombotic complications [5]. This study
suggests that FVII deficiency does not provide protec-
tion from thromboembolism, either arterial or venous,
especially in a surgical setting. The indication for
thromboprophylaxis in high-risk patients (e.g. patients
undergoing major surgery and high-dose RT) still
needs to be formally evaluated, but anecdotal reports
suggest that it does not increase the risk of bleeding
[5].
Table 1. Thrombosis and inhibitors reported to the STER.
Sex/Age
Replacement
therapy FVII:c(%) 00
FVII:c
(%) 150 Clinical setting Event Timing
Severity/Relation
to replacement
Thrombosis
M/8 rFVIIa 15 lg
Kg1 9 43,
FFP 10 IU 9 13
2.3 320 Neurosurgery Cerebral infarct 8th day Serious/Likely
M/23 rFVIIa 30 lg
Kg1 9 3
6 99 Orthopaedic
surgery
SVT 1st day Non-serious/
Likely
M/53 rFVIIa 30 lg
kg1 9 2, 22.5 lg
kg1 9 1, 15 lg
kg1 9 28
4.8 380 Renal transplant Stroke 30 days Serious/Likely
Inhibitors
F/53*
(p.A354V; p.464Hfs)
rFVIIa†,‡ 30 lg
Kg1 9 1, 10 lg
Kg1 9 8
<1§ / Minor surgery High titre10–20 BU Postoperatively Serious/Likely§
M/5* (p.Ser112 Stop) rFVIIa†,‡ 30 lg
Kg1 9 21 days
2§ / Prophylaxis for
CNS bleeding
High titre 38-68.3 BU 3 months¶ Serious/Likely
M/0.5 rFVIIa†,‡ 65 lg
Kg1 9 1/week
1.3§ / Prophylaxis for
CNS bleeding
High titre 5.5-60 BU 5 months¶ Serious/Likely
M/1 rFVIIa†,‡ 31 lg
Kg1 9 3/week
<1§ / Prophylaxis for
GI bleeding
High titre 32–72 BU 1 month¶ Serious/Likely
Brackets report FVII gene mutation, SVT, superficial vein thrombosis. Age is expressed in years.
*inh. detected centrally.
†Schedule refers to RT prior to inhibitor(inh). detection.
‡All patients received different treatments (pdFVII, FFP) before inh. detection.
§Baseline levels.
¶Age at inhibitor screening.
BU=Bethesda Units.
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An important issue regards the frequency of surgery
as a clinical setting associated with AEs, at least in
this report (57.1%). Considering the reported AEs and
the other side-effects (n = 11, data not shown), surgi-
cal interventions appear to play a not negligible role
in the occurrence of adverse events (RR 2.5,
P = 0.0574, CI 0.97–6.54).
This study focusing on AEs checked prospectively in
a large number of patients with FVII deficiency and
over a large array of clinical settings highlights a low-
to-very-low incidence of AEs. This indicates a very
good safety-to-efficacy ratio, especially for rFVIIa, the
most used replacement treatment.
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